The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solutionResearch in context

The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solutionResearch in context

Liver tumors account for approximately 2% of all pediatric malignancies. Children with advanced stages of hepatoblastoma (HB) are cured only 50–70% of the time while children with advanced hepatocellular carcinoma (HCC) have a

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EClinicalMedicine 2024-03, Vol.69, p.102446
Hauptverfasser: Allison F. O’Neill, Angela Trobaugh-Lotrario, James I. Geller, Eiso Hiyama, Kenichiro Watanabe, Isabelle Aerts, Brice Fresneau, Fabienne Toutain, Michael J. Sullivan, Howard M. Katzenstein, Bruce Morland, Sophie Branchereau, József Zsiros, Rudolf Maibach, Marc Ansari
Format: Artikel
Sprache:eng
Schlagworte:
Carcinoma
Hepatoblastoma
Pediatric
Registry
Relapse
Review
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Liver tumors account for approximately 2% of all pediatric malignancies. Children with advanced stages of hepatoblastoma (HB) are cured only 50–70% of the time while children with advanced hepatocellular carcinoma (HCC) have a
ISSN:2589-5370